Updates from COMMANDS Trial: Luspatercept in Lower-Risk MDS

Opinion
Video

Following ASH 2023, Andrew Brunner, MD, reviews key updates from the COMMANDS trial investigating frontline luspatercept in patients with lower-risk MDS.

Related Videos
A panel of 5 experts on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Video 8 - "Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression"
Video 7 - "The Importance of Thyroidectomy in DTC Patient Care"
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Eric S. Christenson, MD
A panel of 4 experts on colorectal cancer